Ketek is contraindicated in patients with myasthenia gravis. There have been reports of fatal and life-threatening respiratory failure in patients with myasthenia gravis associated with the use of Ketek. (See CONTRAINDICATIONS.)
KETEK tablets contain telithromycin, a semisynthetic antibacterial in the ketolide class for oral administration.
KETEK tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years old and above.
Acute bacterial exacerbation of chronic bronchitis due to
Streptococcus pneumoniae, Haemophilus influenzae, or
Acute bacterial sinusitis due to
Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, or
Community-acquired pneumonia (of mild to moderate severity) due to
Streptococcus pneumoniae, (including multi-drug resistant isolates [MDRSP * ]),
Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, or
*MDRSP, Multi-drug resistant
includes isolates known as PRSP (penicillin-resistant
Streptococcus pneumoniae), and are isolates resistant to two or more of the following antibiotics: penicillin, 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Published Studies Related to Ketek (Telithromycin)
Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone. [2010.01]
The aim of this study is to determine whether the inhibition of CYP2D6 and CYP3A4 enzyme activity with telithromycin affects the pharmacokinetics and pharmacodynamics of orally administered oxycodone in a randomized 2-phase crossover study. Eleven healthy subjects were pretreated with 800 mg of oral telithromycin or placebo for 4 days...
Controlled Trial of a 5-Day Course of Telithromycin versus Doxycycline for Treatment of Mild to Moderate Scrub Typhus. [2007.06]
New antibiotics are required to have the antibacterial activity against doxycycline-resistant Orientia tsutsugamushi. An in vitro sensitivity study showed that telithromycin was more effective than erythromycin for Rickettsia, Bartonella, and Coxiella burnetii... Telithromycin could be considered a promising new antibacterial agent for patients with scrub typhus.
Controlled Trial: 5-day Course of Telithromycin versus Doxycycline for the Treatment of Mild to Moderate Scrub Typhus. [2007.04.02]
New antibiotics are required to have the antibacterial activity against doxycyline-resistant O... Telithromycin could be considered as a promising new antibacterial agent for patients with scrub typhus.
The effect of telithromycin in acute exacerbations of asthma. [2006.04.13]
BACKGROUND: We conducted a double-blind, randomized, placebo-controlled study to evaluate the efficacy of telithromycin in patients with acute exacerbations of asthma... CONCLUSIONS: This study provides evidence of the benefit of telithromycin in patients with acute exacerbations of asthma; the mechanisms of benefit remain unclear. (ClinicalTrials.gov number, NCT00273520.). Copyright 2006 Massachusetts Medical Society.
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. [2006.03]
BACKGROUND AND OBJECTIVE: The antidiabetic repaglinide is metabolized by cytochrome P450 (CYP) 2C8 and CYP3A4. Telithromycin, an antimicrobial agent, inhibits CYP3A4 in vitro and in vivo. Montelukast, an antiasthmatic drug, is a potent inhibitor of CYP2C8 in vitro. We studied the effects of telithromycin, montelukast, and the combination of telithromycin and montelukast on the pharmacokinetics and pharmacodynamics of repaglinide... CONCLUSIONS: Telithromycin increases the plasma concentrations and blood glucose-lowering effect of repaglinide by inhibiting its CYP3A4-catalyzed biotransformation and may increase the risk of hypoglycemia. Unexpectedly, montelukast has no significant effect on repaglinide pharmacokinetics, suggesting that it does not significantly inhibit CYP2C8 in vivo. The low free fraction of montelukast in plasma may explain the lack of effect on CYP2C8 in vivo, despite the low in vitro inhibition constant, highlighting the importance of incorporating plasma protein binding to interaction predictions.
Clinical Trials Related to Ketek (Telithromycin)
TELI TON - Telithromycin in Tonsillitis [Terminated]
This is a multinational, randomized (1: 1), double blind, double dummy,
comparator-controlled, 2 parallel treatment group study in subjects from 6 months to < 13
years of age, with Streptococcus pyogenes tonsillitis/pharyngitis (T/P).Each subject will
receive either telithromycin 25 mg/kg once daily for 5 days or penicillin V, 13. 3 mg/kg
three times daily for 10 days. Matching placebo for telithromycin and penicillin V will also
be dispensed for 5 and 10 days respectively, to provide blinding to the different treatment
regimens. A positive rapid identification test for streptococcal Group A antigen will be
required for all subjects at Visit 1 (Day 1) for entry into the study. Throat swab specimens
for bacterial culture, identification, and antibiotic-susceptibility testing will be taken
at Visits 1, 3 and 4.
Intrapulmonary Pharmacokinetics of Antibiotics [Terminated]
The major objectives of this research are to see how much, and for how long, telithromycin
and azithromycin get into the fluids and cells of the lung.
TELI TAD - Telithromycin in Tonsillitis in Adolescents and Adults [Terminated]
This is a multinational, randomized (1: 1), double blind, comparator-controlled, 2 parallel
treatment group study in subjects equal to or over 13 years of age, with Streptococcus
pyogenes tonsillitis/pharyngitis (T/P). Each subject will receive either telithromycin, 400
mg over-encapsulated tablets, 800 mg once daily for 5 days or penicillin V 250 mg
over-encapsulated tablets, 500 mg three times daily for 10days. Matching placebo capsules
will be dispensed to maintain the blind between the treatment groups. A positive rapid
identification test for streptococcal Group A antigen will be required for all subjects at
Visit 1 (Day 1) for entry into the study. Throat swab specimens for bacterial culture,
identification, and antibiotic-susceptibility testing will be taken at Visits 1, 3 and 4.
KEYS: Study Comparing Clinical Health Outcomes of Telithromycin Versus Azithromycin in Outpatients With Community-acquired Lower Respiratory Tract Infections [Terminated]
The purpose of this study is to determine if 1 course of antibiotic treatment with
telithromycin is superior to azithromycin in the treatment of lower respiratory tract
infections (LRTIs), acute exacerbations of chronic bronchitis (AECBs) and community-acquired
pneumonia (CAP) in the community setting.
Ketek in CAP / AECB in Ambulatory Adult Patients [Completed]
Reports of Suspected Ketek (Telithromycin) Side Effects
Stevens-Johnson Syndrome (2),
Confusional State (1),
Rectal Haemorrhage (1),
Drug Interaction (1),
Lactic Acidosis (1),
Tricuspid Valve Incompetence (1),
Diplopia (1), more >>
Page last updated: 2010-10-05